Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3522567 | 0.76 | CPB2 (0.47) | CPB2 | |
| SCHEMBL28245268 | 0.74 | GABRR1 (0.31) | — | |
| SCHEMBL29282406 | 0.73 | GRIK1 (0.44) | — | |
| SCHEMBL28283750 | 0.73 | GRIK1 (0.44) | — | |
| SCHEMBL16097118 | 0.73 | MGLL (0.46) | — | |
| SCHEMBL27742728 | 0.71 | CPB2 (0.42) | GSRCPB2DPP7DPP8DPP9 | |
| SCHEMBL2158216 | 0.71 | GRIK1 (0.42) | — | |
| SCHEMBL3963136 | 0.70 | GRIK1 (0.41) | — | |
| SCHEMBL28317076 | 0.70 | SLC1A2 (0.41) | DPP7 | |
| SCHEMBL25186742 | 0.69 | GSR (0.48) | GSRCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1968969-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007071396-A2 | PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | GSR 2792/4885F2 275/4885CPB2 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.